Juan Sierra Madero

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2019 · 212 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

Pedro Cahn, Jaime Andrade‐Villanueva, José Ramón Arribas et al. · The Lancet Infectious Diseases · 2014 · 156 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Mortality During the First Year of Potent Antiretroviral Therapy in HIV-1-Infected Patients in 7 Sites Throughout Latin America and the Caribbean

Suely Tuboi, Mauro Schechter, Catherine C. McGowan et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2009 · 82 citations · Full text

Public Health, Health Sciences, Infectious Diseases +14

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis

Mark Boyd, Cecilia L. Moore, Jean‐Michel Molina et al. · The Lancet HIV · 2015 · 80 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +16